Ratings Alnylam Pharmaceuticals, Inc. BOERSE MUENCHEN

Equities

DUL

US02043Q1076

Market Closed - BOERSE MUENCHEN Other stock markets 03:43:29 2024-07-16 pm EDT			5-day change	1st Jan Change
230.7 ^EUR	-2.29%		+0.43%	+33.39%

Jul. 15	Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing	MT
Jul. 03	Jerome Powell did it again

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 69% by 2026.
The company is in a robust financial situation considering its net cash and margin position.
Sales forecast by analysts have been recently revised upwards.
For several months, analysts have been revising their EPS estimates roughly upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALNYLAM PHARMACEUTICALS, INC.	+33.39%	32.4B	-
MODERNA, INC.	+25.83%	46.56B	B-
LONZA GROUP AG	+45.38%	41.67B	A
IQVIA HOLDINGS INC.	+0.69%	41.16B	B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B	B-
CELLTRION, INC.	-6.35%	28.1B	C
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B	B+
MEDPACE HOLDINGS, INC.	+49.18%	13.74B	C+
BIO-TECHNE CORPORATION	+3.45%	12.17B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.85%	11.14B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes